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Abstract
Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial 
lung disease that is, by definition, progressive. Progression 
of IPF is reflected by a decline in lung function, worsening of 
dyspnea and exercise capacity, and deterioration in health-
related quality of life. In the short term, the course of disease 
for an individual patient is impossible to predict. A period of 
relative stability in forced vital capacity (FVC) does not mean 
that FVC will remain stable in the near future. Frequent mon-
itoring using multiple assessments, not limited to pulmo-
nary function tests, is important to evaluate disease progres-
sion in individual patients and ensure that patients are of-
fered appropriate care. Optimal management of IPF requires 
a multidimensional approach, including both pharmacolog-
ical therapy to slow decline in lung function and supportive 
care to preserve patients’ quality of life.
© 2019 The Author(s) 
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic pro-
gressive fibrosing interstitial lung disease (ILD) charac-
terized by the presence of a usual interstitial pneumonia 
pattern on high-resolution computed tomography 
(HRCT) [1]. Diagnosis is recommended to be made in the 
context of a multidisciplinary discussion. IPF tends to af-
fect adults in their sixties or seventies who have a history 
of smoking and is more commonly observed in men than 
in women [2–5]. Patients typically present with chronic 
dyspnea and a dry nonproductive cough and have 
“Velcro”-like bibasilar crackles on chest auscultation [1, 
3]. The reported incidence and prevalence of IPF vary 
widely depending on the methodology used to define cas-
es, but its incidence in North America and Europe, based 
on a systematic review of population-based studies, has 
been conservatively estimated as between 3 and 9 cases 
per 100,000 persons per year [6].
The prevailing hypothesis for the pathogenesis of IPF 
is that the disease is caused by persistent micro-injury to 
the alveolar epithelium combined with an abnormal re-
pair process. Continued replacement of alveolar tissue 
with fibrotic lesions distorts the lung architecture, result-
ing in a reduction in lung volume, impaired gas exchange, 
and ultimately in death [7]. Median survival after diagno-
sis of IPF is approximately 3–4 years [2, 8, 9]. However, 
the clinical course of IPF is variable between patients [10]. 
Some patients die shortly after diagnosis, while others ex-
perience a slower decline over time, and some show peri-
ods of clinical stability interspersed with episodes of rap-
id respiratory deterioration known as acute exacerbations 
[11]. Acute exacerbations are devastating events associ-
ated with very high mortality; in-hospital mortality fol-
lowing an acute exacerbation is estimated to be over 50% 
[11]. Although acute exacerbations are more common in 
patients with advanced lung function impairment, they 
can occur at any time, including in patients with pre-
served lung function [12, 13].
In this review, we will discuss the manifestations of 
disease progression in patients with IPF, how disease pro-
gression can be evaluated, and the importance of taking a 
multifaceted and individualized approach to the moni-
toring and management of IPF. This article is based on 
discussions held at a meeting attended by the authors in 
June 2017, as well as a review of the scientific literature.
Progression of IPF
IPF is, by definition, a progressive disease [1]. Progres-
sion of IPF is typically reflected in a decline in forced vital 
capacity (FVC), worsening of dyspnea, a reduction in ex-
ercise capacity, and deterioration in health-related qual-
ity of life (HRQL) [5, 14, 15]. Data from clinical trials sug-
gest that in patients with mild or moderate lung function 
impairment at baseline, the decline in FVC in patients 
who receive placebo is approximately 150–200 mL over 1 
year (Fig. 1) [16]. Decline in FVC is a strong predictor of 
mortality in patients with IPF. In a pooled analysis of data 
from the placebo groups of the TOMORROW, INPUL-
SIS, CAPACITY, and ASCEND trials, patients who had 
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Fig. 1. Lung function decline in patients 
with IPF treated with placebo in Phase II 
and III clinical trials [16]. Red dots denote 
the mean or median change from baseline 
in FVC or VC in the placebo groups of 
Phase II and III clinical trials in patients 
with IPF. The black line denotes the mean 
decline in FVC in healthy subjects aged 60 
years based on FVC measurements taken 
between 1987–1989, 1990–1992, and 2011– 
2013 [87]. Reproduced with permission of 
the © ERS 2019 [16]. This material has not 
been reviewed prior to release; therefore, 
the European Respiratory Society may not 
be responsible for any errors, omissions, or 
inaccuracies, or for any consequences aris-
ing there from, in the content. FVC, forced 
vital capacity; IPF, idiopathic pulmonary 
fibrosis.
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an FVC decline ≥10 to < 15% predicted had a more than 
two-fold greater risk of mortality during the trials than 
patients who had an FVC decline < 5% predicted (Fig. 2) 
[17]. Other studies have shown even greater risks of mor-
tality associated with decline in FVC ≥10% predicted 
[12]. Patients with low FVC, or with documented decline 
in FVC, are also more likely to experience an acute exac-
erbation [12, 18].
While these data from clinical trials are useful for char-
acterizing the progression of IPF at a population level, for 
an individual patient, the situation is much more com-
plex. At present, there is no means of making an accurate 
prediction of disease course for an individual patient. Pri-
or rate of change in FVC appears to be a poor predictor 
of subsequent change in FVC (Fig. 3) [19]. In the INPUL-
SIS trials, placebo-treated patients with well-preserved 
FVC (FVC > 90% predicted) at baseline had almost ex-
actly the same decline in FVC over 1 year as patients with 
less well-preserved FVC (–225 vs. –224 mL/year, respec-
tively) [13]. Preservation of FVC in patients with IPF 
should not be regarded as indicating that FVC will remain 
stable in the future. A period of stability in FVC does not 
mean that the disease is not progressing at a subclinical 
level or that the patient is not at risk of an acute exacerba-
tion or death. A seminal study found that even in patients 
with stable FVC over 6 months, median survival was only 
3 years [20]. Thus, it is important that measures other 
than FVC are taken into account in the evaluation of dis-
ease progression in an individual patient.
Gas exchange, measured by the diffusing capacity of 
the lungs for carbon monoxide (DLco), is reduced in pa-
tients with IPF and declines as the disease progresses [14, 
21]. A decline in DLco > 15% predicted over 6–12 months 
is associated with a significantly increased risk of mortal-
ity in patients with IPF [5, 22]. Difficulties in standard-
izing measurements across centers make DLco a chal-
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Fig. 2. Risk of mortality in patients treated with placebo in the TO-
MORROW, INPULSIS, CAPACITY, and ASCEND trials in sub-
groups by baseline variables, decline in FVC, and acute exacerba-
tions (adapted from [17]). Comparisons were made to reference 
levels: age < 65 years, never smoker, FVC > 85% predicted, DLco > 
50% predicted, FVC decline < 5% predicted, no acute exacerbation. 
Reprinted with permission of the American Thoracic Society. 
Copyright © 2019 American Thoracic Society [17]. FVC, forced 
vital capacity.
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lenging end point to use in clinical trials, but in clinical 
practice, it is a useful tool for assessing disease progres-
sion in an individual patient.
The functional deterioration that occurs as IPF pro-
gresses is reflected in a diminishing of exercise capacity. 
In a study of 748 patients, a reduction in the distance 
walked during a 6-min walk test of > 50 m over 24 weeks 
was associated with a nearly three-fold increase in mor-
tality over the following year [23]. Oxygen desaturation 
during exercise (reduction of > 10% from baseline) has 
also been associated with a significantly increased risk of 
mortality [24]. A requirement for supplemental oxygen, 
initially during exertion and then later also at rest, is a 
marker of advanced disease in patients with IPF and a 
strong predictor of mortality [21, 22, 25, 26]. In a real-
world cohort of 167 patients with IPF, median survival 
after initiation of oxygen therapy was < 18 months, com-
pared with approximately 49 months for patients not us-
ing supplemental oxygen [21].
The symptoms of IPF, particularly cough and dyspnea, 
invariably worsen as the disease progresses [14, 27]. 
Cough has been shown to be an independent predictor of 
disease progression (defined as a decline in FVC ≥10% 
predicted, decline in DLco ≥15% predicted, lung trans-
plantation, or death) in the following 6 months [28]. An 
increase in the severity of dyspnea is also a predictor of 
mortality [22, 29]. Cough and dyspnea are major deter-
minants of HRQL among patients with IPF [14, 27, 30]. 
As IPF progresses, worsening of symptoms makes it dif-
ficult for patients to perform tasks requiring even mild 
exertion, with impacts on many aspects of patients’ lives 
including family, social participation, and employment 
[27, 31]. Thus, for an individual patient, worsening of 
symptoms can be the most debilitating aspect of the pro-
gression of the disease.
There is increasing evidence that the extent of fibrosis 
on HRCT, and of specific features evident on HRCT such 
as reticular patterns with architectural distortion and ves-
sel-related structures, and changes in these over time are 
predictors of mortality in patients with IPF [32–34]. How-
ever, in clinical practice, it is currently not possible to use 
changes in HRCT scans as a means of assessing disease 
progression. More research is needed to validate comput-
erized scoring systems against outcomes. At present, there 
is no consensus as to when repeat HRCT scans should be 
performed in the monitoring of patients with IPF. The 
identification and validation of genetic and molecular bio-
markers that predict disease progression is also an active 
area of research [35–38], but the integration of biomarkers 
into clinical practice remains some time away.
Given the shortcomings of single assessments as pre-
dictors of mortality in patients with IPF, multivariate 
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Fig. 3. Trajectory of FVC following stability or decline in previous year (adapted from [19]). Mixed-models anal-
ysis of trend in FVC. Solid lines indicate mean FVC; dashed lines indicate 95% CI. Reprinted from [19]. Copyright 
(2019) with permission from the American College of Chest Physicians; permission conveyed through Copyright 
Clearance Center, Inc. FVC, forced vital capacity.
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models have been developed, including the GAP (gender, 
age, physiology) index and staging system [39], the com-
posite physiologic index [40], and the risk stratification 
score [41]. However, none of these provides an accurate 
prediction of disease course for an individual patient, and 
none has been widely implemented in clinical practice.
Monitoring Patients with IPF
Frequent monitoring is essential to evaluate disease 
progression in patients with IPF and so inform therapeu-
tic decisions and patient counseling. Pulmonary function 
tests (PFTs) are a vital part of patient monitoring, but 
given that FVC decline is not the only indicator of disease 
progression in patients with IPF, follow-up assessments 
should not be limited to PFTs. While there is little evi-
dence available to define the optimal interval between 
clinic visits, we regard visits with assessments of FVC and 
DLco every 3–4 months as reasonable for monitoring dis-
ease progression and for maintaining a good relationship 
with the patient. A disadvantage of performing PFTs at 
this frequency is that given the noise in FVC measure-
ments, a number of measurements may be needed to de-
tect a decline in FVC, leading to a significant lag time 
before FVC decline is identified and delays to decisions 
on treatment. More frequent monitoring of FVC using 
home spirometry may enable earlier detection of FVC de-
cline and acute exacerbations [42–44], but its utility in 
everyday practice has yet to be established. In interpreting 
measurements of FVC and DLco, clinicians should be 
mindful of the potential confounding effects of concomi-
tant emphysema; in patients with an extent of emphyse-
ma ≥15%, FVC may not be a reliable measure for assess-
ing disease progression [45].
Symptoms and HRQL can be assessed at every clinical 
visit through open-ended questions and the use of ques-
tionnaires [46, 47]. However, no short, disease-specific 
questionnaire to assess the overall severity and impact of 
the disease has been validated in patients with IPF. The 
severity and impact of dyspnea can be difficult to deter-
mine without an understanding of the level of activity 
normally undertaken by the patient; exertional dyspnea 
in a patient who is elderly and infirm is not comparable 
to that in an individual who has remained active. Patients 
who report only mild dyspnea may have reduced the se-
verity of their dyspnea by reducing their mobility. The use 
of quantitative metrics such as the University of Califor-
nia San Diego Shortness of Breath Questionnaire [48], 
Medical Research Council dyspnea scale [49], or Borg 
scale [50] can be of value in the assessment of changes in 
dyspnea as IPF progresses.
The 6-min walk test is a simple test that can be valuable 
in the assessment and follow-up of patients with IPF. If 
serial tests are used, it is important that the same meth-
odology is used for all tests, including consistency in the 
delivery of supplemental oxygen (else differences in the 
provision of supplemental oxygen should be considered 
in the interpretation of test results) [51, 52]. Training ef-
fects and the potential impact of comorbidities should 
also be taken into account in the interpretation of follow-
up test results. Oxygen saturation should be measured 
during the test and into the recovery period. An oxygen 
desaturation < 88% during exercise is generally used as a 
guideline for prescribing supplemental oxygen. Oxygen 
saturation at rest should be measured at every clinic visit 
and the results considered in deciding on patient care.
Slowing the Progression of IPF
All patients with IPF should be informed about access 
to treatments that slow disease progression. Two antifi-
brotic drugs, nintedanib [53] and pirfenidone [54], have 
been approved for the treatment of IPF. In large, placebo-
controlled trials in patients with IPF and mild or moder-
ate impairment in FVC at baseline, nintedanib [55] and 
pirfenidone [56] each reduced decline in FVC by approx-
imately 50% over 1 year. Further, there was some evi-
dence that these therapies reduced the risk of acute respi-
ratory worsenings [18, 57]. Treatment guidelines issued 
by ATS/ERS/JRS/ALAT in July 2015 provided condition-
al recommendations for the use of nintedanib and pir-
fenidone in patients with IPF, recognizing that different 
choices will be appropriate for individual patients and 
that clinicians must help patients arrive at a decision 
about their management [58]. These recommendations 
are echoed in country-specific treatment guidelines and 
position statements authored by regional experts [59–
63]. Importantly, data from clinical trials showed that 
nintedanib and pirfenidone had the same effect on FVC 
decline across the spectrum of baseline FVC investigated 
(FVC > 50% predicted) [13, 64–67]. These data, combined 
with the unpredictable nature of disease progression in 
patients with IPF, and the fact that FVC is not the only 
indicator of disease severity or progression argue against 
a “watch and wait” approach to treatment.
The latest international treatment guidelines also 
provided a conditional recommendation for the use of 
anti-acid therapy in patients with IPF and asymptom-
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atic gastroesophageal reflux disease, based on very low-
quality evidence [58]; however, in the absence of ran-
domized controlled trials, the risk:benefit of anti-acid 
medications in patients with IPF remains unknown [68, 
69]. All other pharmacological therapies that have been 
used in the treatment of IPF, including N-acetylcysteine, 
received strong or conditional recommendations against 
their use [58]. Lung transplantation is an option for a 
minority of patients with IPF, with guidelines recom-
mending that patients be evaluated for transplant at an 
early stage [70].
Symptom Management and Supportive Care
Symptom management and supportive care are im-
portant elements of the management of IPF (Fig.  4). 
Symptom control presents great challenges to clinicians, 
as the dyspnea, cough, and fatigue associated with IPF 
are difficult to manage, with little evidence available to 
inform therapeutic decision-making. Although oral 
corticosteroids and opiates are sometimes used to re-
lieve cough and dyspnea, the benefits of these therapies 
have not been established [71, 72]. Supplemental oxygen 
is recommended in international treatment guidelines 
for patients with IPF and clinically significant resting 
hypoxemia [58]. A recent randomized study showed 
that supplemental oxygen provided benefits on HRQL 
in patients with ILD and exertional hypoxia [73], but 
more evidence is needed on its optimal use in patients 
with ILD [74]. Pulmonary rehabilitation is recommend-
ed in treatment guidelines [75] and has been shown in 
short-term studies to provide improvements in exercise 
capacity, dyspnea, and quality of life in patients with IPF 
[76].
The identification and management of comorbid 
conditions is an important part of optimizing outcomes 
and HRQL in patients with IPF [77, 78]. Many patients 
with IPF have comorbid respiratory and nonrespiratory 
conditions that complicate their disease, such as pulmo-
nary hypertension, chronic obstructive pulmonary dis-
ease, emphysema, gastroesophageal reflux disease, car-
diovascular disease, obstructive sleep apnea, and de-
pression.
Patient Education and Communication
A lack of appropriate information remains a challenge 
for patients with IPF and their caregivers [79, 80]. Much 
of the information about IPF provided on the Internet is 
outdated and inaccurate [81]. Although patients require 
information at the time of diagnosis, some issues may be 
better discussed at a later stage, according to the needs of 
the patient [82]. In addition to general information, pa-
tients value practical advice on how to manage their dis-
ease and maximize their quality of life [83]. It is essential 
that clinicians explain to patients and their caregivers that 
IPF is an intrinsically progressive disease so that they un-
derstand the value of taking therapies that slow disease 
progression even though their disease will continue to 
progress and their symptoms are not relieved. In particu-
lar, patients should be made aware that a history of rela-
tively stable disease does not rule out a significant decline 
in lung function in the near future or the occurrence of 
an acute exacerbation. A structured, patient-centered 
communication approach is recommended to ensure that 
patients are supported in coming to an informed decision 
about how their disease should be managed [84].
Supportive/palliative care aims to improve or main-
tain HRQL as far as possible by relieving symptoms and 
providing support to patients and their caregivers to 
help them manage the impact of the disease and reduce 
fears about the future [85]. Supportive care may be pro-
vided on a one-to-one basis, via patient support groups, 
as part of pulmonary rehabilitation programs, or within 
Symptom-centred
approaches
End-of-life care Best supportive
care
Patient-centred
management Caregiver-centredmanagement
Disease-stabilizing
care
Optimized
quality-of-life
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Fig. 4. A multifaceted approach to managing patients with IPF 
(adapted from [88]). Reprinted from [88]. Copyright (2019) with 
permission from Elsevier; permission conveyed through Copy-
right Clearance Center, Inc.
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an in-patient setting [85]. Specialist nurses can play a 
key role in providing advice and support to patients. 
Given the unpredictable course of IPF, supportive care 
should be integrated into discussions with patients and 
their caregivers at an early stage [85, 86]. End-of-life 
planning can be a difficult issue for patients and their 
families to discuss, and the timing and volume of infor-
mation should be individualized to the needs of the pa-
tient [87, 88].
Conclusions
IPF is an intrinsically progressive disease with a poor 
prognosis. Although predictors of disease progression 
and mortality have been identified in clinical trials and 
epidemiological studies, the course of disease for an in-
dividual patient remains impossible to predict. Progres-
sion of IPF is reflected by a decline in FVC, worsening of 
symptoms and exercise capacity, and deterioration in 
HRQL, but significant variability is observed between 
patients. A period of relative stability in FVC should not 
be interpreted as meaning that the disease is not pro-
gressing at a subclinical level or that FVC will remain 
stable in the near future. Frequent monitoring using 
multiple assessments including PFTs and measurements 
of functional capacity, symptoms, and HRQL is impor-
tant to evaluate disease progression in individual patients 
and ensure that patients are offered appropriate care 
throughout the course of their disease. Optimal manage-
ment of IPF requires a multidimensional approach, in-
cluding both pharmacological therapy and supportive 
care.
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